Solicitation of Nominations for Membership on the Secretary's Advisory Committee on Human Research Protections, 71004-71005 [E8-27851]
Download as PDF
71004
Federal Register / Vol. 73, No. 227 / Monday, November 24, 2008 / Notices
sroberts on PROD1PC70 with NOTICES
and other in vitro alternative test
methods be considered prior to in vivo
pyrogenicity testing, where determined
appropriate for a specific testing
situation.
NICEATM also announces availability
of the final ICCVAM Background Review
Document: Validation Status of Five In
Vitro Test Methods Proposed for
Assessing Potential Pyrogenicity of
Pharmaceuticals and Other Products
(NIH Publication 08–6391). The final
background review document (BRD)
provides the data and analyses used to
assess the current validation status of
these five in vitro test methods.
The ICCVAM TMER and supporting
BRDs have been forwarded to U.S.
Federal agencies for regulatory and
other acceptance consideration, where
applicable. Responses received will be
posted on the NICEATM–ICCVAM Web
site.
ADDRESSES: Electronic copies of the
ICCVAM TMER and final BRD are
available from the NICEATM–ICCVAM
Web site at https://iccvam.niehs.nih.gov
or by contacting NICEATM (see FOR
FURTHER INFORMATION CONTACT).
FOR FURTHER INFORMATION CONTACT: Dr.
William S. Stokes, Director, NICEATM,
NIEHS, P.O. Box 12233, MD EC–17,
Research Triangle Park, NC 27709,
(telephone) 919–541–2384, (fax) 919–
541–0947, (e-mail)
niceatm@niehs.nih.gov Courier address:
NICEATM, NIEHS, 79 T.W. Alexander
Drive, Building 4401, Room 3128,
Research Triangle Park, NC 27709.
SUPPLEMENTARY INFORMATION:
Background
In 2005, the European Centre for the
Validation of Alternative Methods
(ECVAM), a unit of the Institute for
Health and Consumer Protection at the
European Commission’s Joint Research
Centre, submitted BRDs for five in vitro
pyrogen test methods proposed as
replacements for the RPT to ICCVAM
for formal evaluation of their scientific
validity for regulatory testing purposes.
ICCVAM unanimously agreed that the
five submitted in vitro pyrogen test
methods should have high priority for
evaluation. On December 16, 2005,
NICEATM published a Federal Register
notice (Vol. 70, No. 241, pages 74833–
74834), requesting public comments on
the appropriateness and relative priority
of convening an independent peer
review panel (Panel) to evaluate the
validation status of the five in vitro
pyrogen test methods, the nomination of
scientists to serve on the Panel, and the
submission of data from in vivo and in
vitro pyrogenicity testing. Based on the
ECVAM BRDs as well as data and
VerDate Aug<31>2005
19:32 Nov 21, 2008
Jkt 217001
information submitted in response to
the aforementioned Federal Register
notice, NICEATM subsequently
compiled a comprehensive draft BRD on
the five in vitro pyrogen test methods
and released it for public comment on
December 12, 2006 (Vol. 71, No. 238,
pages 74533–74534).
On February 6, 2007, NICEATM and
ICCVAM convened a Panel to review
the ICCVAM draft BRD for errors and
omissions and to evaluate the validation
status of the five in vitro pyrogen test
methods. The Panel also reviewed the
extent that the information contained in
the ICCVAM draft BRD supported the
ICCVAM draft test method
recommendations for proposed test
method uses, standardized protocols,
test method performance standards, and
additional studies. The Panel
considered public comments made at
the Panel meeting, as well as public
comments submitted in advance of the
meeting, before concluding their
deliberations. NICEATM made the
Panel’s report available in May 2007
(Vol. 72, No. 89, pages 26395–26396).
The ICCVAM draft BRD and draft
recommendations, the Panel’s report,
and all public comments were made
available to the Scientific Advisory
Committee on Alternative Toxicological
Methods (SACATM) for review and
comment at their meeting on June 12,
2007 (Vol. 72, No. 83, pages 23831–
23832).
ICCVAM considered the Panel’s
report, all public comments, and the
comments of SACATM in finalizing its
recommendations on the use of these
five in vitro test methods proposed for
assessing potential pyrogenicity of
pharmaceuticals and other products.
The ICCVAM TMER includes the
ICCVAM recommendations on uses and
limitations for each test method,
standardized protocols, future studies,
and the development of performance
standards, as well as the Panel’s report
and Federal Register notices. The final
BRD, which provides the supporting
documentation for this report, is
available as a separate document.
ICCVAM forwarded the ICCVAM TMER
and the supporting final BRD to U.S.
Federal agencies for consideration, in
accordance with the ICCVAM
Authorization Act of 2000 (42 U.S.C.
285l–3). Agency responses to the
ICCVAM test method recommendations
will be made available on the
NICEATM–ICCVAM Web site as they
are received.
Background Information on ICCVAM,
NICEATM, and SACATM
ICCVAM is an interagency committee
composed of representatives from 15
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Federal regulatory and research agencies
that use, generate, or disseminate
toxicological information. ICCVAM
conducts technical evaluations of new,
revised, and alternative methods with
regulatory applicability and promotes
the scientific validation and regulatory
acceptance of toxicological test methods
that more accurately assess the safety
and hazards of chemicals and products
and that refine, reduce, and replace
animal use. The ICCVAM Authorization
Act of 2000 established ICCVAM as a
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers ICCVAM and provides
scientific and operational support for
ICCVAM-related activities. NICEATM
and ICCVAM work collaboratively to
evaluate new and improved test
methods applicable to the needs of U.S.
Federal agencies. Additional
information about ICCVAM and
NICEATM can be found at https://
www.iccvam.niehs.nih.gov.
SACATM was established January 9,
2002 (Vol. 67, No. 49, page 11358), and
is composed of scientists from the
public and private sectors. SACATM
provides advice to the Director of the
NIEHS, to ICCVAM, and to NICEATM
regarding the statutorily mandated
duties of ICCVAM and activities of
NICEATM. Additional information
about SACATM, including the charter,
roster, and records of past meetings, can
be found at https://ntp.niehs.nih.gov/go/
167.
Dated: November 7, 2008.
Samuel H. Wilson,
Acting Director, National Institute of
Environmental Health Sciences and National
Toxicology Program.
[FR Doc. E8–27790 Filed 11–21–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation of Nominations for
Membership on the Secretary’s
Advisory Committee on Human
Research Protections
Department of Health and
Human Services, Office of the Secretary,
Office of Public Health and Science.
ACTION: Notice.
AGENCY:
Authority: 42 U.S.C. 217a, Section 222 of
the Public Health Service Act, as amended.
The Committee is governed by the provisions
of Public Law 92–463, as amended (5 U.S.C.
Appendix 2), which sets forth standards for
the formation and use of advisory
committees.
SUMMARY: The Office for Human
Research Protections (OHRP), a program
E:\FR\FM\24NON1.SGM
24NON1
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 73, No. 227 / Monday, November 24, 2008 / Notices
office in the Office of Public Health and
Science, Department of Health and
Human Services (HHS), is seeking
nominations of qualified candidates to
be considered for appointment as
members of the Secretary’s Advisory
Committee on Human Research
Protections (SACHRP). SACHRP
provides advice and recommendations
to the Secretary, HHS, and the Assistant
Secretary for Health on matters
pertaining to the continuance and
improvement of functions within the
authority of HHS directed toward
protections for human subjects in
research. SACHRP was established by
the Secretary, HHS, on October 1, 2002.
OHRP is seeking nominations of
qualified candidates to fill two positions
on the Committee membership that will
be vacated in June of 2009.
DATES: Nominations for membership on
the Committee must be received no later
than January 23, 2009.
ADDRESSES: Nominations should be
mailed or delivered to Dr. Jerry
Menikoff, Director, Office for Human
Research Protections, Department of
Health and Human Services, 1101
Wootton Parkway, Suite 200; Rockville,
MD 20852. Nominations also may be
sent via e-mail to sachrp@hhs.gov or via
facsimile at 240–453–6909.
FOR FURTHER INFORMATION CONTACT: Julia
Gorey, Executive Director, SACHRP,
Office for Human Research Protections,
1101 Wootton Parkway, Suite 200,
Rockville, MD 20852, telephone: 240–
453–8141. A copy of the Committee
charter and list of the current members
can be obtained by contacting Ms.
Gorey, accessing the SACHRP Web site
at https://www.hhs.gov/ohrp/sachrp, or
requesting via e-mail at sachrp@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Committee provides advice on matters
pertaining to the continuance and
improvement of functions within the
authority of HHS directed toward
protections for human subjects in
research. Specifically, the Committee
provides advice relating to the
responsible conduct of research
involving human subjects with
particular emphasis on special
populations such as neonates and
children, prisoners, the decisionally
impaired, pregnant women, embryos
and fetuses, individuals and
populations in international studies,
investigator conflicts of interest and
populations in which there are
individually identifiable samples, data,
or information.
In addition, the Committee is
responsible for reviewing selected
ongoing work and planned activities of
the OHRP and other offices/agencies
VerDate Aug<31>2005
19:32 Nov 21, 2008
Jkt 217001
within HHS responsible for human
subjects protection. These evaluations
may include, but are not limited to, a
review of assurance systems, the
application of minimal research risk
standards, the granting of waivers,
education programs sponsored by
OHRP, and the ongoing monitoring and
oversight of institutional review boards
and the institutions that sponsor
research.
Nominations: The Office for Human
Research Protections is requesting
nominations to fill two positions for
voting members of SACHRP. The two
positions will become vacant in June of
2009. Nominations of potential
candidates for consideration are being
sought from a wide array of fields,
including, but not limited to: public
health and medicine, behavioral and
social sciences, health administration,
and biomedical ethics.
To qualify for consideration of
appointment to the Committee, an
individual must possess demonstrated
experience and expertise in any of the
several disciplines and fields pertinent
to human subjects protection and/or
clinical research.
The individuals selected for
appointment to the Committee can be
invited to serve a term of up to four
years. Committee members receive a
stipend and reimbursement for per diem
and any travel expenses incurred for
attending Committee meetings and/or
conducting other business in the
interest of the Committee.
Nominations should be typewritten.
The following information should be
included in the package of material
submitted for each individual being
nominated for consideration: (1) A letter
of nomination that clearly states the
name and affiliation of the nominee, the
basis for the nomination (i.e. , specific
attributes which qualify the nominee for
service in this capacity), and a statement
that the nominee is willing to serve as
a member of the Committee; (2) the
nominator’s name, address and daytime
telephone number, and the home and/
or work address, telephone number, and
email address of the individual being
nominated; and (3) a current copy of the
nominee’s curriculum vitae. Federal
employees should not be nominated for
consideration of appointment to this
Committee.
The Department makes every effort to
ensure that the membership of HHS
Federal advisory committees is fairly
balanced in terms of points of view
represented and the committee’s
function. Every effort is made to ensure
that individuals from a broad
representation of geographic areas,
women and men, ethnic and minority
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
71005
groups, and the disabled are given
consideration for membership on HHS
Federal advisory committees.
Appointment to this Committee shall be
made without discrimination on the
basis of age, race, ethnicity, gender,
sexual orientation, disability, and
cultural, religious, or socioeconomic
status.
Documentation must be included in
the nomination to indicate that the
nominated individual is willing to serve
as a member of SACHRP. Individuals
who are selected to be considered for
appointment will be required to provide
detailed information regarding their
financial holdings, consultancies, and
research grants or contracts. Disclosure
of this information is necessary in order
to determine if the selected candidate is
involved in any activity that may pose
a potential conflict with the official
duties to be performed as a member of
SACHRP.
Dated: November 18, 2008.
Jerry Menikoff,
Director, Office for Human Research
Protections, Executive Secretary, Secretary’s
Advisory Committee on Human Research
Protections.
[FR Doc. E8–27851 Filed 11–21–08; 8:45 am]
BILLING CODE 4150–36–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Agency Recordkeeping/Reporting
Requirements Under Emergency
Review by the Office of Management
and Budget (OMB)
Title: Indian Tribes, Tribal
Organizations or Tribal Consortia Letter
of Intent to Operate a Title IV–E
Program.
OMB No.: New Collection.
Description: The Fostering
Connections to Success and Increasing
Adoptions Act of 2008 (Pub. L. 110–
351) added section 479B to the Social
Security Act (the Act), which allows
Indian Tribes the option to apply to the
Secretary to receive Federal funding to
support the administration of their own
foster care, adoption assistance and
relative guardianship programs under
title IV–E of the Act. The law also
amended the Act at section 476(c)(2)(ii)
to allow Indian Tribes to receive onetime development grants of up to
$300,000 to be used to offset the cost of
developing a title IV–E plan to carry out
the requirements of section 479B of the
Act, and required ACF to provide
technical assistance and
E:\FR\FM\24NON1.SGM
24NON1
Agencies
[Federal Register Volume 73, Number 227 (Monday, November 24, 2008)]
[Notices]
[Pages 71004-71005]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-27851]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation of Nominations for Membership on the Secretary's
Advisory Committee on Human Research Protections
AGENCY: Department of Health and Human Services, Office of the
Secretary, Office of Public Health and Science.
ACTION: Notice.
-----------------------------------------------------------------------
Authority: 42 U.S.C. 217a, Section 222 of the Public Health
Service Act, as amended. The Committee is governed by the provisions
of Public Law 92-463, as amended (5 U.S.C. Appendix 2), which sets
forth standards for the formation and use of advisory committees.
SUMMARY: The Office for Human Research Protections (OHRP), a program
[[Page 71005]]
office in the Office of Public Health and Science, Department of Health
and Human Services (HHS), is seeking nominations of qualified
candidates to be considered for appointment as members of the
Secretary's Advisory Committee on Human Research Protections (SACHRP).
SACHRP provides advice and recommendations to the Secretary, HHS, and
the Assistant Secretary for Health on matters pertaining to the
continuance and improvement of functions within the authority of HHS
directed toward protections for human subjects in research. SACHRP was
established by the Secretary, HHS, on October 1, 2002. OHRP is seeking
nominations of qualified candidates to fill two positions on the
Committee membership that will be vacated in June of 2009.
DATES: Nominations for membership on the Committee must be received no
later than January 23, 2009.
ADDRESSES: Nominations should be mailed or delivered to Dr. Jerry
Menikoff, Director, Office for Human Research Protections, Department
of Health and Human Services, 1101 Wootton Parkway, Suite 200;
Rockville, MD 20852. Nominations also may be sent via e-mail to
sachrp@hhs.gov or via facsimile at 240-453-6909.
FOR FURTHER INFORMATION CONTACT: Julia Gorey, Executive Director,
SACHRP, Office for Human Research Protections, 1101 Wootton Parkway,
Suite 200, Rockville, MD 20852, telephone: 240-453-8141. A copy of the
Committee charter and list of the current members can be obtained by
contacting Ms. Gorey, accessing the SACHRP Web site at https://www.hhs.gov/ohrp/sachrp, or requesting via e-mail at sachrp@hhs.gov.
SUPPLEMENTARY INFORMATION: The Committee provides advice on matters
pertaining to the continuance and improvement of functions within the
authority of HHS directed toward protections for human subjects in
research. Specifically, the Committee provides advice relating to the
responsible conduct of research involving human subjects with
particular emphasis on special populations such as neonates and
children, prisoners, the decisionally impaired, pregnant women, embryos
and fetuses, individuals and populations in international studies,
investigator conflicts of interest and populations in which there are
individually identifiable samples, data, or information.
In addition, the Committee is responsible for reviewing selected
ongoing work and planned activities of the OHRP and other offices/
agencies within HHS responsible for human subjects protection. These
evaluations may include, but are not limited to, a review of assurance
systems, the application of minimal research risk standards, the
granting of waivers, education programs sponsored by OHRP, and the
ongoing monitoring and oversight of institutional review boards and the
institutions that sponsor research.
Nominations: The Office for Human Research Protections is
requesting nominations to fill two positions for voting members of
SACHRP. The two positions will become vacant in June of 2009.
Nominations of potential candidates for consideration are being sought
from a wide array of fields, including, but not limited to: public
health and medicine, behavioral and social sciences, health
administration, and biomedical ethics.
To qualify for consideration of appointment to the Committee, an
individual must possess demonstrated experience and expertise in any of
the several disciplines and fields pertinent to human subjects
protection and/or clinical research.
The individuals selected for appointment to the Committee can be
invited to serve a term of up to four years. Committee members receive
a stipend and reimbursement for per diem and any travel expenses
incurred for attending Committee meetings and/or conducting other
business in the interest of the Committee.
Nominations should be typewritten. The following information should
be included in the package of material submitted for each individual
being nominated for consideration: (1) A letter of nomination that
clearly states the name and affiliation of the nominee, the basis for
the nomination (i.e. , specific attributes which qualify the nominee
for service in this capacity), and a statement that the nominee is
willing to serve as a member of the Committee; (2) the nominator's
name, address and daytime telephone number, and the home and/or work
address, telephone number, and email address of the individual being
nominated; and (3) a current copy of the nominee's curriculum vitae.
Federal employees should not be nominated for consideration of
appointment to this Committee.
The Department makes every effort to ensure that the membership of
HHS Federal advisory committees is fairly balanced in terms of points
of view represented and the committee's function. Every effort is made
to ensure that individuals from a broad representation of geographic
areas, women and men, ethnic and minority groups, and the disabled are
given consideration for membership on HHS Federal advisory committees.
Appointment to this Committee shall be made without discrimination on
the basis of age, race, ethnicity, gender, sexual orientation,
disability, and cultural, religious, or socioeconomic status.
Documentation must be included in the nomination to indicate that
the nominated individual is willing to serve as a member of SACHRP.
Individuals who are selected to be considered for appointment will be
required to provide detailed information regarding their financial
holdings, consultancies, and research grants or contracts. Disclosure
of this information is necessary in order to determine if the selected
candidate is involved in any activity that may pose a potential
conflict with the official duties to be performed as a member of
SACHRP.
Dated: November 18, 2008.
Jerry Menikoff,
Director, Office for Human Research Protections, Executive Secretary,
Secretary's Advisory Committee on Human Research Protections.
[FR Doc. E8-27851 Filed 11-21-08; 8:45 am]
BILLING CODE 4150-36-P